Aldeyra Therapeutics, Inc. ALDX
Regular-session close
After hours · Nov 19, 7:31 PM ET
- YTD
- -86.07%
- 1 year
- -85.15%
5D +0.1006 (+16.23%)
- Market cap
- 43.56M
- EPS (ttm)
- -0.34
- Shares out
- 59.55M
- Forward P/E
- -7.80
- YTD return
- -86.07%
- 1-year return
- -85.15%
- 50-day average
- 5.12
- 200-day average
- 4.48
- Enterprise value
- 233.47M
- Volume
- 850.56K
- Avg volume
- 1.14M
- Open
- 0.68
- Previous close
- 0.6711
- Day's range
- 0.6087 – 0.7386
- 52-week range
- 0.527 – 5.93
- Beta
- 1.43
- Analysts
- Strong Buy
- Price target
- 10.00 (+1285.6%)
Key statistics
- Price / book
- 3.33
- Free cash flow
- -57.67M
- Total cash
- 72.74M
- Total debt
- 15.61M
- Return on equity
- -43.05%
- Short % of float
- 6.90%
Fundamental scorecard
5 of 25 checks passed on ALDX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.25 | -0.25 | 0.00 | 0.00% |
| Oct 3, 2024 | Jun 1, 2024 | -0.21 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.08 | -0.14 | -0.06 | -75.00% |
| Mar 7, 2024 | Dec 1, 2023 | -0.21 | -0.08 | +0.13 | +61.90% |
| Nov 3, 2023 | Sep 1, 2023 | 0.00 | -0.14 | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.31 | -0.15 | +0.16 | +51.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 3, 2024 | Oppenheimer | up | Perform | Outperform |
| Oct 17, 2023 | Citigroup | main | Buy | Buy |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aldeyra.com
News
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics to Host Regulatory Update Webcast
Levicept Appoints Darlene Deptula-Hicks as CFO
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Your note
Sign in to keep a note on ALDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY TODD C | Chief Executive Officer | Sale | Mar 11, 2024 | 1,471,300 |
| BRONSTEIN BEN | Director | Conversion of Exercise of derivative security | Jun 26, 2023 | 28,248 |
| GREENBERG BRUCE | Chief Financial Officer | Sale | Aug 11, 2024 | 126,382 |
| MACHATHA STEPHEN | Officer | Sale | Aug 11, 2024 | 236,771 |
| MILLER-RICH NANCY | Director | Purchase | Apr 11, 2023 | 922 |
| PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.58% | 9,275,851 | 44.11M | Sep 29, 2024 |
| Knoll Capital Management, LLC | 9.19% | 5,475,516 | 26.04M | Sep 29, 2024 |
| Vanguard Group Inc | 6.32% | 3,760,619 | 17.88M | Sep 29, 2024 |
| Blackrock Inc. | 6.27% | 3,734,408 | 17.76M | Sep 29, 2024 |
| Kennedy Capital Management, Inc. | 3.16% | 1,881,078 | 8.94M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.87% | 1,114,628 | 5.30M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 1,758,714 | 8.36M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.18% | 1,296,318 | 6.16M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 697,567 | 3.32M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.14% | 680,004 | 3.23M | Jul 30, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 1.07% | 635,905 | 3.02M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 510,128 | 2.43M | Aug 30, 2024 |
